Keith A. Goldan

Keith A. Goldan

DirectoratSyndax Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-13% from the year before · Syndax Pharmaceuticals stock +58.9% the same year

Keith A. Goldan was paid $2.5M in FY2025 (Dec), down 13%. Syndax Pharmaceuticals stock rose 58.9% that year.

Pay$100 in the stock at the end of FY21 → $96
Pay is from the Summary Compensation Table of each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Abeona TherapeuticsPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Syndax PharmaceuticalsPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role -35%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?